What is KineMed?
KineMed, based in California, stands as a global leader in the identification and measurement of dynamic biochemical processes critical to understanding and managing disease. The company's core strength lies in its patented dynamic proteomics technology platform, which, combined with deep biological expertise, aims to accelerate and reduce the costs associated with diagnostic and therapeutic research and development. KineMed actively seeks collaborations across the pharmaceutical, CRO, histopathology, diagnostics, medical instruments, and biotechnology sectors to expand its portfolio and impact.
How much funding has KineMed raised?
KineMed has raised a total of $17.1M across 2 funding rounds:
Other Financing Round
$15M
Private Equity
$2.1M
Other Financing Round (2007): $15M with participation from Stanford Financial Group
Private Equity (2015): $2.1M, investors not publicly disclosed
Key Investors in KineMed
Stanford Financial Group
Stanford Financial Group is an entity that has participated in KineMed's funding rounds, suggesting an interest in the company's technological advancements in the life sciences sector.
What's next for KineMed?
The substantial enterprise-level funding and recent major strategic investment indicate KineMed is in a robust phase of growth and operational scaling. This capital infusion is expected to fuel further development of its proprietary proteomics technology, expand its collaborative partnerships, and accelerate the commercialization of its solutions for drug development and disease management. KineMed's focus on de-risking and optimizing the R&D pipeline positions it for continued leadership in the biopharmaceutical innovation landscape.
See full KineMed company page
